Mackenzie C. Sturdivant

Mackenzie Sturdivant practices at Encompass Health Rehabilitation Hospital of Erie in Erie, Pennsylvania, part of Encompass Health.

Mackenzie Sturdivant's NPI, 1144646902, was assigned on March 17, 2014. Mackenzie Sturdivant holds Pennsylvania license MA059111.

Mackenzie Sturdivant's primary practice is Encompass Health Rehabilitation Hospital of Erie, at 143 East Second Street, Erie, PA 16507 in Erie County. The practice phone is (814) 878-1200.

Mackenzie Sturdivant's primary practice is Encompass Health Rehabilitation Hospital of Erie in Erie, Pennsylvania, part of Encompass Health. Mackenzie Sturdivant is also affiliated with UPMC Hamot. The medical group on file is UPMC Hamot. Dmand AI also links Mackenzie Sturdivant to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mackenzie Sturdivant practices, 3 sites in all. Vendor and product names are available with a free account.

Physician assistant is Mackenzie Sturdivant's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Mackenzie Sturdivant is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Mackenzie Sturdivant is licensed in Pennsylvania.

Dmand AI lists gastroenteritis and itchy rashes among the conditions Mackenzie Sturdivant treats.

CMS data shows 144 Medicare services from Mackenzie Sturdivant across 4 procedure codes in 2024, for 135 Medicare patients. Medicare paid $9,189 for them. Every service was in an office.

CMS counts 135 Medicare patients who saw Mackenzie Sturdivant in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mackenzie Sturdivant's median patient age at 57, with 57% women.

In 2024, Mackenzie Sturdivant wrote 933 Medicare Part D claims for 311 patients. 89% of them were for generic drugs. CMS names the drug for 776 of them, across 13 drugs with 11 or more claims each, at $47,130 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Mackenzie Sturdivant for performance year 2024, reported as part of a group. Mackenzie Sturdivant accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 5 general payments to Mackenzie Sturdivant from 4 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $99.